Since its establishment, Bioceltix has already raised several million USD from private investors and public grants. Shareholders believe in our vision – as one of the first companies in the world, we plan to go through the full authorization procedure with the European Medicines Agency for a veterinary medicinal product using stem cells as active substance. This is a real breakthrough in veterinary medicine that the market has been looking forward to for years. We are the first company that, along with conducting research on stem cell efficacy, has simultaneously developed the technology of their large-scale growing.
Before we decided to go public, we obviously considered debt financing. However, it is no secret that companies at an early stage of development that do not generate positive cash flows are generally unable to service such debt and are not creditworthy. For biotech companies with additional research-related risks inherent in the industry, it is extremely difficult to obtain funding. On the Polish capital market there are still relatively few investors who are willing to accept this level of risk, especially when combined with the lack of liquidity characteristic of private investments. This is where the stock exchange can be really helpful.
We have opted for stock exchange debut not only because of the possibility of obtaining additional financing, but also for the sake of added value. As a listed company, we become more transparent and credible. This is not only important for financial investors, but also helps us build a strong position in negotiations with potential industry partners. As a listed company, we are able to significantly increase our circle of potential investors.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...Article
Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...Article
According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...Article
Gazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...Article
We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...Article
2019? It’s been a good year for Bioceltix. A victory in the Start-Up Challenge coupled with participation in accelerator programs as well as ...Read full
Mamstartup: Gallant has developed a non invasive method for retrieving stem cells which can be used to treat various ailments – from torn ...Read full
Business Insider caught up with Łukasz Bzdzion, founder of the startup Bioceltix, who – together with his team – is developing ...Read full